ArticleResearch square2026
Seroprevalence of measles-specific IgG and genotype-specific neutralizing antibody responses in clinically confirmed cases during the 2021-2023 measles outbreaks in Liberia.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Since 2021, Liberia has experienced disruptive outbreaks of measles across all of its 15 counties, despite the availability of a safe, effective vaccine. There is no data on the potential role of vaccine-induced immunity and no study on seroprevalence of measles-specific IgG in Liberia. Furthermore, there is no data on genotype-specific variation in antibody effectiveness in Liberia. This study evaluated the seroprevalence of measles virus (MeV)-specific IgG in clinically diagnosed patients in Liberia and assessed the breadth of neutralization against four genotypes. Methods: Samples collected retrospectively from 2021 to 2023 and prospective samples collected in 2023 from clinically diagnosed measles cases were analyzed in this study. Study participants included both vaccinated and unvaccinated individuals. MeV-specific IgG antibody was assessed using an enzyme-linked immunosorbent assay. Neutralizing antibodies against the Edmonston, B3, D4, and D8 MeV genotypes were measured using vesicular stomatitis virus pseudotype-based neutralization assays. Results: Overall, 69.9% of 199 individuals, including 100 vaccinees that were clinically diagnosed with measles, tested positive for MeV-specific IgG antibodies. MeV-specific IgG positivity was higher in vaccinated (52.5%) than in unvaccinated individuals (8.6%). Strong neutralization was observed against the D8 genotype in 98.9% of seropositive individuals, compared to 94.7% against Edmonston and D4 genotypes and 91.6% against B3. Significantly higher neutralization titers were observed in vaccinated compared to unvaccinated individuals for all four genotypes (p < 0.0001). There was a weak positive correlation between IgG levels, neutralizing titers, and participant age. Conclusion: The findings demonstrate strong genotype-cross-neutralizing immunity among vaccinated and seropositive patients, highlighting the critical role of measles vaccination in maintaining effective antibody protection. The significant percentage of seronegative patients indicates ongoing vulnerability to measles transmission and reinforces the need to improve vaccination coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.